288 related articles for article (PubMed ID: 31309149)
1. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen JS; Laursen LG; Schuster MB; Pundhir S; Schoof E; Ge Y; d'Altri T; Vitting-Seerup K; Rapin N; Gentil C; Jendholm J; Theilgaard-Mönch K; Reckzeh K; Bullinger L; Döhner K; Hokland P; Fitzgibbon J; Porse BT
Sci Adv; 2019 Jul; 5(7):eaaw4304. PubMed ID: 31309149
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
[TBL] [Abstract][Full Text] [Related]
3. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
[TBL] [Abstract][Full Text] [Related]
4. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
[TBL] [Abstract][Full Text] [Related]
8. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.
Haefliger S; Klebig C; Schaubitzer K; Schardt J; Timchenko N; Mueller BU; Pabst T
Blood; 2011 Jun; 117(22):5931-40. PubMed ID: 21471526
[TBL] [Abstract][Full Text] [Related]
9. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
[TBL] [Abstract][Full Text] [Related]
10. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.
Kuo YY; Hou HA; Chen YK; Li LY; Chen PH; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Chou WC; Liu CY; Tang JL; Yao M; Tien HF
Haematologica; 2014 Dec; 99(12):1799-807. PubMed ID: 25193961
[TBL] [Abstract][Full Text] [Related]
12. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract][Full Text] [Related]
13. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
Wouters BJ; Löwenberg B; Erpelinck-Verschueren CA; van Putten WL; Valk PJ; Delwel R
Blood; 2009 Mar; 113(13):3088-91. PubMed ID: 19171880
[TBL] [Abstract][Full Text] [Related]
14. Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia.
Schardt JA; Eyholzer M; Timchenko NA; Mueller BU; Pabst T
J Cell Mol Med; 2010 Jun; 14(6B):1509-19. PubMed ID: 19659458
[TBL] [Abstract][Full Text] [Related]
15. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
17.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
18. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
[TBL] [Abstract][Full Text] [Related]
19. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
Wang LM; Xiao HW; Huang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
[TBL] [Abstract][Full Text] [Related]
20. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.
Wouters BJ; Jordà MA; Keeshan K; Louwers I; Erpelinck-Verschueren CA; Tielemans D; Langerak AW; He Y; Yashiro-Ohtani Y; Zhang P; Hetherington CJ; Verhaak RG; Valk PJ; Löwenberg B; Tenen DG; Pear WS; Delwel R
Blood; 2007 Nov; 110(10):3706-14. PubMed ID: 17671232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]